GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Omeros Corporation (OMER) [hlAlert]

Rating:
Outperform
OMER
up 111.26 %

Omeros (OMER) rated Outperform with price target $12 by Wedbush Morgan

Posted on: Friday,  Nov 20, 2009  2:25 PM ET by Wedbush Morgan

Wedbush Morgan rated Outperform Omeros Corporation (NASDAQ: OMER) on 11/20/2009, when the stock price was $7.46. Since
then, Omeros Corporation has gained 111.26% as of 01/26/2016's recent price of $15.76.
If you would have followed this Wedbush Morgan's recommendation on OMER, you would have gained 111.26% of your investment in 2258 days.

Omeros Corporation is a clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company?s clinically advanced product candidates are derived from its PharmacoSurgerytm platform designed to improve the clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Its PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery.

Since 1980, WEDBUSH has used its private equity discipline to invest in under-valued and capital constrained public and private companies that have a significant potential for appreciation. The firm invests with high quality management teams with domain expertise and expects management to retain or make a personally significant equity investment.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/20/2009 2:25 PM Buy
None
7.46 12.00
as of 12/31/2009
1 Week down  -2.77 %
1 Month up  2.79 %
3 Months down  -0.28 %
1 YTD down  -0.28 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy